Lack of benefit from premedication for pegylated asparaginase during pediatric acute lymphoblastic leukemia/lymphoma therapy: A side‐by‐side comparison
Pediatric Blood & Cancer · 2024
DOI: 10.1002/pbc.30716 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Sarah Menig und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Seattle Children's Hospital, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Drug Hypersensitivity, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Hypersensitivity. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Leukemia and Lymphoma Society.
Abstract (Originalsprache)
Background
Pegylated l ‐asparaginase (PEG) is integral to treatment regimens for acute lymphoblastic leukemia (ALL) and lymphoma. Hypersensitivity reactions (HSRs) to PEG are common and can preclude continued administration. Data supporting recommendations for universal premedication (UPM) prior to PEG infusion to reduce incidence of HSRs are limited; UPM has become common practice. Procedures Two free‐standing children's hospitals independently implemented UPM prior to PEG infusions in 2016 and 2019, respectively. In a side‐by‐side retrospective analysis, incidence and severity of HSRs were analyzed pre‐ and postimplementation of UPM in youth ≥1 years old treated with frontline PEG‐containing ALL regimens (2015–2018, 2016–2020). All HSRs were centrally reviewed within each institution to confirm and grade the HSR (Common Terminology Criteria for Adverse Events, v5). Planned analyses of subsets at potentially greater risk for HSRs included intensive PEG regimens (≥5 doses), adolescent and young adults (AYA), Hispanic/Latinx ethnicity, and obesity.
Results
In 410 patients (by institution, n = 282 and n = 128), the overall incidence of Grade ≥ 3 HSRs was 20% (56 out of 282) and 18% (23 out of 128), respectively. No difference in incidence of Grade ≥ 3 HSRs in patients with versus without UPM was found at either institution (23 vs. 19%, p = .487 and 19 vs. 17%, p = .845). UPM also did not reduce the severity of HSRs, nor influence HSR risk within any patient subset.
Conclusions
UPM prior to PEG infusion did not alter incidence or severity of HSRs at either institution. HSR remains a common complication of PEG therapy, impacting the patient experience. Alternative strategies to reduce HSRs are urgently required.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Seattle Children's Hospital, Seattle, Washington, USA.
- Department of Pharmacy, Children's Hospital Los Angeles, Los Angeles, California, USA.
- Department of Pediatrics, University of Washington, Seattle Children's Hospital, Seattle, Washington, USA.
- Department of Pediatrics, University of Southern California, Los Angeles, California, USA.
- Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, California, USA.
ORCID-Profile: Etan Orgel
Förderung
- Leukemia and Lymphoma Society
Zitieren
APA
Menig, S., Dinh, A., Angus, J., Tucker, S., Leger, K. J., Rushing, T., & Orgel, E. (2024). Lack of benefit from premedication for pegylated asparaginase during pediatric acute lymphoblastic leukemia/lymphoma therapy: A side‐by‐side comparison. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30716
Vancouver
Menig S, Dinh A, Angus J, Tucker S, Leger KJ, Rushing T, et al. Lack of benefit from premedication for pegylated asparaginase during pediatric acute lymphoblastic leukemia/lymphoma therapy: A side‐by‐side comparison. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.30716
BibTeX
@article{Menig2024,
author = {Menig, Sarah and Dinh, Andrew and Angus, Jonathan and Tucker, Sarah and Leger, Kasey J and Rushing, Teresa and Orgel, Etan},
title = {Lack of benefit from premedication for pegylated asparaginase during pediatric acute lymphoblastic leukemia/lymphoma therapy: A side‐by‐side comparison},
journal = {Pediatric Blood & Cancer},
year = {2024},
doi = {10.1002/pbc.30716}
}
EUVIMED